Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) dropped 3.1% during trading on Friday . The company traded as low as $1.72 and last traded at $1.72. Approximately 2,213 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 13,160 shares. The stock had previously closed at $1.78.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a report on Saturday, September 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye has a consensus rating of “Reduce” and a consensus target price of $9.00.
Read Our Latest Stock Analysis on ANL
Adlai Nortye Stock Down 3.1%
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
See Also
- Five stocks we like better than Adlai Nortye
- Best Aerospace Stocks Investing
- After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
- Options Trading – Understanding Strike Price
- Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
